Skip to main content
  • FDA Not Ready to Grant Premarket Approval of Lutonix DCB for Use Below the Knee

    The U.S. Food and Drug Administration indicated that a premarket approval application seeking to allow the Lutonix drug-coated balloon to treat peripheral artery disease below the knee is “not approvable in its current form,” BD Chairman and CEO Vincent A. Forlenza told investors last week.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details